» Articles » PMID: 39161757

Cardiovascular Adverse Event Reporting in Psoriasis and Psoriatic Arthritis Biological Therapy Clinical Trials

Overview
Publisher Wolters Kluwer
Date 2024 Aug 20
PMID 39161757
Authors
Affiliations
Soon will be listed here.
References
1.
Wu J, Kavanaugh A, Lebwohl M, Gniadecki R, Merola J . Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(6):797-806. PMC: 9313585. DOI: 10.1111/jdv.18044. View

2.
Masson W, Lobo M, Molinero G . Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther. 2020; 37(5):2017-2033. PMC: 7467489. DOI: 10.1007/s12325-020-01346-6. View

3.
Armstrong A, Read C . Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. DOI: 10.1001/jama.2020.4006. View

4.
Armstrong A, Mehta M, Schupp C, Gondo G, Bell S, Griffiths C . Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021; 157(8):940-946. PMC: 8246333. DOI: 10.1001/jamadermatol.2021.2007. View

5.
F Alexis A, Blackcloud P . Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014; 7(11):16-24. PMC: 4255694. View